gabapentin market name gabapentin tablet 800 mg

The Gabapentin Market is segmented by formulation, distribution channel, and region from 2023 to 2033. The gabapentin market is registering a valuation of USD 2.11 billion in 2023 and is estimated to reach USD 3.54 billion by 2033. The market is securing a CAGR of 5.3% during the forecast period. Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication primarily used to treat neuropathic pain and also for partial seizures [10] [7] of epilepsy. It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy , postherpetic neuralgia , and central pain . [ 11 ] The global gabapentin market size was estimated at USD 2.25 billion in 2024 and is projected to grow at a CAGR of 5.2% from 2025 to 2030. “Marketresearch.biz reports that the Gabapentin Market size is expected to be approximately USD 5.7 Bn in 2032, up from USD 2.9 Bn as of 2022. This is increasing at a rate of (CAGR) 7.2% over the duration from 2023 until 2032.Gabapentin Market OverviewGabapentin, a medication primarily used to treat epilepsy and neu It is expected to continue growing at a CAGR of 4.38%, reaching USD 3.00 billion by 2030. Gabapentin is a medication primarily used to treat nerve-related pain and seizure disorders. Its market scope encompasses various applications, including the management of neuropathic pain, epilepsy, and migraine prevention. Global Gabapentin Market Overview. As per MRFR analysis, the Gabapentin Market Size was estimated at 2.44 (USD Billion) in 2024. The Gabapentin Market Industry is expected to grow from 2.58 (USD Billion) in 2025 to 4.32 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.90% during the forecast period (2025 - 2034). The global gabapentin market is expected to continue to grow in the coming years due to the increasing incidence of neuropathic pain and other conditions that are treated with gabapentin. The market is also expected to benefit from the growing awareness of gabapentin as an effective treatment option and the availability of generic versions of The global gabapentin market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.5 Billion by 2033 , exhibiting a growth rate (CAGR) of 4.92% during 2025-2033 . Data Bridge Market Research analyses that the global gabapentin market which was USD 2,472.84 million in 2022, is expected to reach USD 3,021.80 million by 2030, and is expected to undergo a CAGR of 2.6% during the forecast period 2023-2030. The “tablet” segment is expected to dominate the market due to patient’s preference. The global gabapentin market size was valued at USD 2.10 billion in 2024, driven by the increasing use of gabapentin as a pain reliever drug across the globe. The market is anticipated to grow at a CAGR of 5% during the forecast period of 2025-2034 to achieve a value of USD 3.26 billion by 2034. Child 6–11 years 10 mg/kg once daily (max. per dose 300 mg) on day 1, then 10 mg/kg twice daily (max. per dose 300 mg) on day 2, then 10 mg/kg 3 times a day (max. per dose 300 mg) on day 3; usual dose 25–35 mg/kg daily in 3 divided doses, some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate, daily dose maximum to be given in 3 divided The Gabapentin Market will reportedly reach USD3.7 billion by 2032, progressing at a CAGR of 5.9% during the forecast period. Various factors contribute to the dynamics of the Gabapentin market. The rising cases of neuropathic pain conditions and certain neurological disorders that gabapentin is commonly used to treat act as drivers in this market. Horizant is a brand name of gabapentin enacarbil, approved by the FDA in the following formulation(s): HORIZANT (gabapentin enacarbil - tablet, extended release;oral) Manufacturer: AZURITY Approval date: April 6, 2011 Strength(s): 600MG ; Manufacturer: AZURITY Approval date: December 13, 2011 Strength(s): 300MG By Application, the epilepsy segment has held the largest market share in 2024. By Application, the neuropathic pain segment is anticipated to grow at the fastest rate over the projected period. By Distribution Channel, the hospital pharmacy segment registered the highest market share in 2024. Gabapentin enacarbil extended release tablets available under the trade name Horizant and gabapentin are not interchangeable. Use: Postherpetic neuralgia. Usual Adult Dose for Restless Legs Syndrome: Gabapentin enacarbil available under the trade name Horizant: 600 mg orally once daily with food at about 5 PM The global gabapentin market is projected to grow from USD 2.22 billion in 2024 to USD 4.19 billion by 2037, demonstrating a CAGR of over 5% throughout the forecast timeline, from 2025 to 2037. Key industry players include Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC Apotex Inc., Teva Pharmaceutical Industries Ltd., among others. Gabapentin, also known by its brand name Neurontin, is an anticonvulsant medication primarily used to treat seizures and neuropathic pain. It was first approved by the FDA in 1993 and has since gained popularity due to its effectiveness in managing various neurological conditions. Meaning. gabapentin-market-size.jpg. Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Global Gabapentin Market Size, Share & Industry Trends Analysis Report by Application, Dosage Form, Distribution Channel The gabapentin market was estimated to be worth of USD 2.1 billion in 2023 and is estimated to expand at 4.9% CAGR from 2024 to 2032, owing to the expanded indications of gabapentin. US Gabapentin Market industry is evolving rapidly, with trends focusing on Technology innovations, digital transformation, telehealth expansion, value-based care models, AI integration, and personalized medicine.

gabapentin market name gabapentin tablet 800 mg
Rating 5 stars - 733 reviews




Blog

Articles and news, personal stories, interviews with experts.

Video